The polyamine pathway as a potential target for vascular diseases: Focus on restenosis

Current Vascular Pharmacology

Volumn 9, Issue 6, 2011, Pages 706-714

  Forte, Amalia ^a   Hellstrand, Per ^b   Nilsson, Bengt Olof ^b   Grossi, Mario ^a   Rossi, Francesco ^a   Cipollaro, Marilena ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Arginase; DFMO; Negative remodelling; Neointima; Ornithine decarboxylase; Restenosis

Indexed keywords

EFLORNITHINE; ORNITHINE; POLYAMINE; POLYAMINE DERIVATIVE; SPERMIDINE; SPERMINE;

APOPTOSIS; ARTERY GRAFT; ARTICLE; BRAIN ISCHEMIA; CELL MIGRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; DIRECTIONAL ATHERECTOMY; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; IN VIVO STUDY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POLYAMINE SYNTHESIS; RESTENOSIS; REVASCULARIZATION; ROTATIONAL ATHERECTOMY; VASCULAR DISEASE;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CONSTRICTION, PATHOLOGIC; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; POLYAMINES; STENTS; VASCULAR DISEASES;

EID: 80054073475     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111797484116     Document Type: Article

References (88)

1. Hamana K, Matsuzaki S. Polyamines as a chemotaxonomic marker in bacterial systematics. Crit Rev Microbiol 1992; 18: 261-83.
2. Igarashi K, Kashiwagi K. Modulation of cellular function by polyamines. Int J Biochem Cell Biol 2010; 42: 39-51.
3. Nishida K, Abiko T, Ishihara M, Tomikawa M. Arterial injuryinduced smooth muscle cell proliferation in rats is accompanied by increase in polyamine synthesis and level. Atherosclerosis 1990; 83: 119-25.
4. Pendeville H, Carpino N, Marine JC, et al. The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell Biol 2001; 21: 6549-58.
5. Casero RA, Pegg AE. Polyamine catabolism and disease. Biochem J 2009; 421: 323-38.
6. Kahana C. Antizyme and antizyme inhibitor, a regulatory tango. Cell Mol Life Sci 2009; 66: 2479-88.
7. Murakami Y, Suzuki J, Samejima K, et al. The change of antizyme inhibitor expression and its possible role during mammalian cell cycle. Exp Cell Res 2009; 315: 2301-11.
8. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007; 34: 906-11.
9. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001; 15: 1264-6.
10. Wei LH, Jacobs AT, Morris SM, Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 2000; 279: C248-56.
11. Ryoo S, Lemmon CA, Soucy KG, et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006; 99: 951-60.
12. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003; 376: 1-14.
13. Soulet D, Gagnon B, Rivest S, Audette M, Poulin R. A fluorescent probe of polyamine transport accumulates into intracellular acidic vesicles via a two-step mechanism. J Biol Chem 2004; 279: 49355-66.
14. Belting M, Mani K, Jonsson M, et al. Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivital role for nitrosothiol-derived nitric oxide. J Biol Chem 2003; 278: 47181-9.
15. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001; 58: 244-58.
16. Xiao L, Wang JY. Posttranscriptional regulation of gene expression in epithelial cells by polyamines. Methods Mol Biol 2011; 720: 67-79.
17. Zou T, Rao JN, Liu L, et al. Polyamines regulate the stability of JunD mRNA by modulating the competitive binding of its 3' untranslated region to HuR and AUF1. Mol Cell Biol 2010; 30: 5021-32.
18. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-96.
19. Maeda Y, Rachez C, Hawel L, Byus CV, Freedman LP, Sladek FM. Polyamines modulate the interaction between nuclear receptors and vitamin D receptor-interacting protein 205. Mol Endocrinol 2002; 16: 1502-10.
20. Ragnarsson L, Mortensen M, Dodd PR, Lewis RJ. Spermine modulation of the glutamate(NMDA) receptor is differentially responsive to conantokins in normal and Alzheimer's disease human cerebral cortex. J Neurochem 2002; 81: 765-79.
21. Prunotto M, Compagnone A, Bruschi M, et al. Endocellular polyamine availability modulates epithelial-to-mesenchymal transition and unfolded protein response in MDCK cells. Lab Invest 2010; 90: 929-39.
22. Alhonen L, Uimari A, Pietila M, Hyvonen MT, Pirinen E, Keinanen TA. Transgenic animals modelling polyamine metabolismrelated diseases. Essays Biochem 2009; 46: 125-44.
23. Lukkarinen J, Grohn OH, Sinervirta R, et al. Transgenic rats as models for studying the role of ornithine decarboxylase expression in permanent middle cerebral artery occlusion. Stroke 1997; 28: 639-45.
24. Alhonen L, Parkkinen JJ, Keinanen T, Sinervirta R, Herzig KH, Janne J. Activation of polyamine catabolism in transgenic rats induces acute pancreatitis. Proc Natl Acad Sci USA 2000; 97: 8290-5.
25. Laird JR, Dawson DL. The role for cryoplasty in the treatment of infrainguinal artery disease: case studies. J Endovasc Ther 2009; 16: II1 16-28.
26. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci (Lond) 2008; 114: 257-64.
27. Lexis CP, Rahel BM, Meeder JG, Zijlstra F, van der Horst IC. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. Cardiovasc Diabetol 2009; 8: 41.
28. Myit S, Delafontaine P, Bochaton-Piallat ML, Giraud S, Gabbiani G, Brink M. Different growth properties of neointimal and medial smooth muscle cells in response to growth factors. J Vasc Res 2003; 40: 97-104.
29. Shanahan CM, Weissberg PL. Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 333-8.
30. Maeng M, Olesen PG, Emmertsen NC, et al. Time course of vascular remodeling, formation of neointima and formation of neoadven titia after angioplasty in a porcine model. Coron Artery Dis 2001; 12: 285-93.
31. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-9.
32. Justice J, Yacono C. Use of drug-eluting stents for patients with coronary heart disease. JAAPA 2009; 22: 30-4.
33. Auer J, Leitner A, Berent R, Lamm G, Lassnig E, Krennmair G. Long-term outcomes following coronary drug-eluting- and baremetal- stent implantation. Atherosclerosis 2010; 210: 503-9.
34. Ansel GM, Lumsden AB. Evolving modalities for femoropopliteal interventions. J Endovasc Ther 2009; 16: II 82-97.
35. Yavin D, Roberts DJ, Tso M, Sutherland GR, Eliasziw M, Wong JH. Carotid endarterectomy vs. stenting: a meta-analysis of randomized trials. Can J Neurol Sci 2011; 38: 230-5.
36. Forte A, Finicelli M, De Luca P, et al. Expression profiles in surgically- induced carotid stenosis: a combined transcriptomic and proteomic investigation. J Cell Mol Med 2008; 12: 1956-73.
37. Forte A, Galderisi U, De Feo M, et al. C-Myc antisense oligonucleotides preserve smooth muscle differentiation and reduce negative remodelling following rat carotid arteriotomy. J Vasc Res 2005; 42: 214-25.
38. Thyberg J, Fredholm BB. Induction of ornithine decarboxylase activity and putrescine synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Exp Cell Res 1987; 170: 160-9.
39. Odenlund M, Holmqvist B, Baldetorp B, Hellstrand P, Nilsson BO. Polyamine synthesis inhibition induces S phase cell cycle arrest in vascular smooth muscle cells. Amino Acids 2009; 36: 273-82.
40. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-43.
41. Durante W, Liao L, Peyton KJ, Schafer AI. Thrombin stimulates vascular smooth muscle cell polyamine synthesis by inducing cationic amino acid transporter and ornithine decarboxylase gene expression. Circ Res 1998; 83: 217-23.
42. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; 98: 4202-8.
43. Bauer PM, Buga GM, Ignarro LJ. Role of p42/p44 mitogenactivated- protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci USA 2001; 98: 12802-7.
44. Dumont J, Zureik M, Bauters C, et al. Association of OAZ1 gene polymorphisms with subclinical and clinical vascular events. Arterioscler Thromb Vasc Biol 2007; 27: 2120-6.
45. Liang M, Ekblad E, Hellstrand P, Nilsson BO. Polyamine synthesis inhibition attenuates vascular smooth muscle cell migration. J Vasc Res 2004; 41: 141-7.
46. Nilsson BO, Gomez MF, Swärd K, Hellstrand P. Regulation of Ca2+ channel and phosphatase activities by polyamines in intestinal and vascular smooth muscle--implications for cellular growth and contractility. Acta Physiol Scand 2002; 176: 33-41.
47. Swärd K, Nilsson BO, Hellstrand P. Inhibition of polyamine synthesis influences contractility of intestinal smooth muscle in culture. Am J Physiol 1997; 273: C77-84.
48. Tsvilovskyy VV, Zholos AV, Bolton TB. Effects of polyamines on the muscarinic receptor-operated cation current in guinea-pig ileal smooth muscle myocytes. Br J Pharmacol 2004; 143: 968-75.
49. Wang JY, Wang J, Golovina VA, Li L, Platoshyn O, Yuan JX. Role of K(+) channel expression in polyamine-dependent intestinal epithelial cell migration. Am J Physiol Cell Physiol 2000; 278: C303-14.
50. Wei LH, Yang Y, Wu G, Ignarro LJ. IL-4 and IL-13 upregulate ornithine decarboxylase expression by PI3K and MAP kinase pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 2008; 294: C1198-205.
51. Bachetti T, Comini L, Francolini G, et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004; 37: 515-23.
52. Perez-Cano FJ, Franch A, Castellote C, Castell M. Immunomodulatory action of spermine and spermidine on NR8383 macrophage line in various culture conditions. Cell Immunol 2003; 226: 86-94.
53. Bjelakovic G, Stojanovic I, Jevtovic Stoimenov T, et al. Metabolic correlations of glucocorticoids and polyamines in inflammation and apoptosis. Amino Acids 2010; 39: 29-43.
54. Zhang M, Wang H, Tracey KJ. Regulation of macrophage activation and inflammation by spermine: a new chapter in an old story. Crit Care Med 2000; 28: N60-6.
55. Cetrullo S, Tantini B, Facchini A, et al. A pro-survival effect of polyamine depletion on norepinephrine-mediated apoptosis in cardiac cells: role of signaling enzymes. Amino Acids 2010;
56. Ray RM, Viar MJ, Yuan Q, Johnson LR. Polyamine depletion delays apoptosis of rat intestinal epithelial cells. Am J Physiol Cell Physiol 2000; 278: C480-9.
57. Bhattacharya S, Ray RM, Johnson LR. Role of polyamines in p53- dependent apoptosis of intestinal epithelial cells. Cell Signal 2009; 21: 509-22.
58. Tantini B, Fiumana E, Cetrullo S, et al. Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia. J Mol Cell Cardiol 2006; 40: 775-82.
59. Sinha-Hikim I, Shen R, Kovacheva E, Crum A, Vaziri ND, Norris KC. Inhibition of apoptotic signalling in spermine-treated vascular smooth muscle cells by a novel glutathione precursor. Cell Biol Int 2010; 34: 503-11.
60. Brune B, Hartzell P, Nicotera P, Orrenius S. Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp Cell Res 1991; 195: 323-9.
61. Izbicka E, Streeper RT, Yeh IT, et al. Effects of alphadifluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer. Anticancer Res 2010; 30: 2263-9.
62. Zhao YJ, Zhang WH, Xu CQ, et al. Involvement of the ornithine decarboxylase/polyamine system in precondition-induced cardioprotection through an interaction with PKC in rat hearts. Mol Cell Biochem 2009; 332: 135-44.
63. Flamigni F, Stanic I, Facchini A, et al. Polyamine biosynthesis as a target to inhibit apoptosis of non-tumoral cells. Amino Acids 2007; 33: 197-202.
64. Takano K, Ogura M, Yoneda Y, Nakamura Y. Oxidative metabolites are involved in polyamine-induced microglial cell death. Neuroscience 2005; 134: 1123-31.
65. Stefanelli C, Stanic I, Zini M, et al. Polyamines directly induce release of cytochrome c from heart mitochondria. Biochem J 2000; 347 Pt 3: 875-80.
66. Li JM, Zhang X, Nelson PR, et al. Temporal evolution of gene expression in rat carotid artery following balloon angioplasty. J Cell Biochem 2007; 101: 399-410.
67. Endean ED, Kispert JF, Martin KW, O'Connor W. Intimal hyperplasia is reduced by ornithine decarboxylase inhibition. J Surg Res 1991; 50: 634-7.
68. Peyton KJ, Ensenat D, Azam MA, et al. Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler ThrombVasc Biol 2009; 29: 488-94.
69. Thacher TN, Gambillara V, Riche F, Silacci P, Stergiopulos N, da Silva RF. Regulation of arginase pathway in response to wall shear stress. Atherosclerosis 2010; 210: 63-70.
70. Touchard AG, Schwartz RS. Preclinical restenosis models: challenges and successes. Toxicol Pathol 2006; 34: 11-8.
71. Welch JE, Bengtson P, Svensson K, et al. Single chain fragment anti-heparan sulfate antibody targets the polyamine transport system and attenuates polyamine-dependent cell proliferation. Int J Oncol 2008; 32: 749-56.
72. Casero RA, Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007; 6: 373-90.
73. Mitchell JL, Thane TK, Sequeira JM, Marton LJ, Thokala R. Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids 2007; 33: 291-7.
74. Poulin R, Lu L, Ackermann B, Bey P, Pegg AE. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha- difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J Biol Chem 1992; 267: 150-8.
75. Grove J, Fozard JR, Mamont PS. Assay of alphadifluoromethylornithine in body fluids and tissues by automatic amino-acid analysis. J Chromatogr 1981; 223: 409-16.
76. Heby O. Ornithine decarboxylase as target of chemotherapy. Adv Enzyme Regul 1985; 24: 103-24.
77. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-8.
78. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100: 1579-88.
79. Yang J, Zeng Y, Li Y, et al. Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis. Eur J Pharm Sci 2008; 35: 427-34.
80. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, Schafer AI. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 2000; 279: 646-52.
81. Abe T, Sasaki M, Nakajima H, et al. Evaluation of pluronic F127 as a base for gradual release of anticancer drug. Gan To Kagaku Ryoho 1990; 17: 1546-50.
82. Moore T, Croy S, Mallapragada S, Pandit N. Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution: drug release in stirred systems. J Control Release 2000; 67: 191-202.
83. Shirahata A, Pegg AE. Regulation of S-adenosylmethionine decarboxylase activity in rat liver and prostate. J Biol Chem 1985; 260: 9583-8.
84. Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 1994; 54: 3210-7.
85. Rial NS, Meyskens FL, Gerner EW. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. Essays Biochem 2009; 46: 111-24.
86. Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008; 1: 32-8.
87. Bailey HH, Kim K, Verma AK, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}- difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) 2010; 3: 35-47.
88. Simoneau AR, Gerner EW, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebocontrolled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008; 17: 292-9.